Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

dwide patent applications held by or exclusively licensed to DOR, orBec(R) also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively. DOR is also continuing to actively build intellectual property around oral BDP in other inflammatory conditions.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in acute radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The first ... Dose Escalation in First in Human Studies” will cover ... better go/no-go decisions. , With increasing R&D costs and ... companies need to maximize the knowledge collected in early ... and improve success in late stage development. , Next, ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... PARIS, Sept. 7, 2011 Cellectis (Alternext: ... announced that its nuclease production capacity has ... costs. Industrialization of the nuclease manufacturing gives ... commercial subsidiary of Cellectis, the potential to ...
... and OXFORD, England, Sept. 7, 2011 CMC Biologics ... entered into a non-exclusive license agreement providing OBT with ... financial terms of which have not been disclosed, covers ... by OBT. CMC Biologics, CHEF1 cell line development platform ...
... Inc. (Nasdaq: RDEA ) announced today that it ... and Drug Administration (FDA) and successfully reached agreement on the ... plan: the overall size and design of the planned Phase ... proposed for NDA filing, manufacturing plans for both drug substance ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... MADISON A multi-institutional team of researchers has developed ... tract. This safe, noninvasive method for assessing the function ... could lead to better diagnosis and treatment of gut ... bacterial overgrowth, irritable bowel syndrome and inflammatory bowel disease ... serious side effects in patients with diseases such as ...
(Date:7/24/2014)... biodiversity and one of the most species richness biome ... However, current levels of diversity might be still underestimated. ... in the description of new endemic species of this ... availability of samples for DNA analysis. , Using ... morphological analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2New imaging agent provides better picture of the gut 2A tiny new species of frog from Brazil with a heroic name 2
... 10 years has seen a huge increase in the popularity ... kept in our homes are monkeys, tarantulas, iguanas, salamanders, snakes, ... around the world develop their conservation and captive breeding programmes ... of exotic animals. To help develop that ...
... have argued that environmental regulations can negatively impact ... by George Mason University researcher Nicole Darnall shows ... not only offset the costs of regulations, but ... which looked at more than 2,600 manufacturing facilities ...
... give birth to offspring who become even heavier, resulting ... of Medicine researchers in Houston who found that chemical ... phenomenon called epigenetics -- could affect successive generations of ... United States and it,s increasingly recognized as a worldwide ...
Cached Biology News:The exotic side of veterinary science 2The exotic side of veterinary science 3Corporations can profit from being environmentally friendly 2The epigenetics of increasing weight through the generations 2
... DNA Engine Dyad instrument is the most ... Featuring MJ's world-class thermal performance, the Dyad ... as well as point-and-click navigation via touch ... can be easily and economically expanded to ...
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
... RT Telomerase Detection Kit is ... assay for the fluorometric detection ... telomerase activity. It incorporates refinements ... and adds the ability to ...
Biology Products: